Yahoo
NasdaqGS - Nasdaq Real Time Price USD

MiniMed Group, Inc. (MMED)

12.11 -0.23 (-1.86%)
At close: May 1 at 4:00:01 PM EDT
12.25 +0.14 (+1.16%)
After hours: May 1 at 4:31:32 PM EDT
Chart Range Bar
Loading chart for MMED
  • Previous Close 12.34
  • Open 12.35
  • Bid 12.03 x 200
  • Ask 12.24 x 200
  • Day's Range 12.07 - 12.74
  • 52 Week Range 12.01 - 20.48
  • Volume 530,241
  • Avg. Volume 1,169,355
  • Market Cap (intraday) 3.401B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.27
  • Earnings Date Jun 3, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 22.45

MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.

www.minimed.com

8,000

Full Time Employees

April 25

Fiscal Year Ends

Healthcare

Sector

Performance Overview: MMED

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MMED
36.43%
S&P 500 (^GSPC)
5.62%

1-Year Return

MMED
36.43%
S&P 500 (^GSPC)
29.01%

3-Year Return

MMED
36.43%
S&P 500 (^GSPC)
73.47%

5-Year Return

MMED
36.43%
S&P 500 (^GSPC)
72.92%

Earnings Trends: MMED

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 790M
Earnings 19M

Q3

FY26

0
200M
400M
600M

Analyst Insights: MMED

View More

Analyst Price Targets

16.00
22.45 Average
12.11 Current
27.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/1/2026
Analyst Barclays
Rating Action Initiated
Rating Overweight
Price Action Announces
Price Target 26

Statistics: MMED

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    3.39B

  • Enterprise Value

    3.39B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.13

  • Price/Book (mrq)

    0.98

  • Enterprise Value/Revenue

    1.13

  • Enterprise Value/EBITDA

    75.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.71%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.99B

  • Net Income Avi to Common (ttm)

    -320M

  • Diluted EPS (ttm)

    -1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10M

  • Total Debt/Equity (mrq)

    1.76%

  • Levered Free Cash Flow (ttm)

    --

Compare To: MMED

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: MMED

Fair Value

12.11 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: